Clinical Trial Update: Efficacy and Safety of LAS41003 in the Treatment of Superficial Infected Eczema [Phase 2]

View source ↗

Summary

Phase II trial evaluating LAS41003 for superficial infected eczema has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• LAS41003

Snippet

Sponsor: Almirall, S.A. | Conditions: Eczema | Phase 2 | Status: COMPLETED